Last reviewed · How we verify

OPTIMOX-bevacizumab — Competitive Intelligence Brief

OPTIMOX-bevacizumab (OPTIMOX-bevacizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (bevacizumab component) + chemotherapy regimen. Area: Oncology.

phase 3 Monoclonal antibody (bevacizumab component) + chemotherapy regimen VEGF (vascular endothelial growth factor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

OPTIMOX-bevacizumab (OPTIMOX-bevacizumab) — GERCOR - Multidisciplinary Oncology Cooperative Group. OPTIMOX-bevacizumab combines oxaliplatin-based chemotherapy with bevacizumab, a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
OPTIMOX-bevacizumab TARGET OPTIMOX-bevacizumab GERCOR - Multidisciplinary Oncology Cooperative Group phase 3 Monoclonal antibody (bevacizumab component) + chemotherapy regimen VEGF (vascular endothelial growth factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (bevacizumab component) + chemotherapy regimen class)

  1. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OPTIMOX-bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/optimox-bevacizumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: